3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
7
Terminated
2
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
29
Breast Neoplasms
21
Carcinoma, Non-Small-Cell Lung
20
Triple Negative Breast Neoplasms
15
Lung Neoplasms
10
Colorectal Neoplasms
8
Neoplasm Metastasis
7
Esophageal Squamous Cell Carcinoma
7
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Esophageal Neoplasms
5
Ovarian Neoplasms
4
Biliary Tract Neoplasms
4
Head and Neck Neoplasms
3
Gallbladder Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Pancreatic Ductal
3
Vaccinia
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms by Site
2
Neoplasms
2
Locally Advanced Pancreatic Cancer
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Brain Neoplasms
2
Advanced Solid Tumors
2
Adenocarcinoma
2
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Interventions
Cisplatin
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
11
Specimen Handling
10
Paclitaxel
6
Platinum
5
Cyclophosphamide
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
4
durvalumab
4
cemiplimab
4
Radiotherapy, Intensity-Modulated
4
Radiotherapy
3
Pemetrexed
3
Oxaliplatin
3
Nivolumab
3
Fluorouracil
3
Cetuximab
3
Carboplatin
3
Biopsy
3
poly ICLC
2
fludarabine phosphate
2
cabozantinib
2
atezolizumab
2
Radiation
2
Ipilimumab
2
Interviews as Topic
2
Heavy Ion Radiotherapy
2
Gemcitabine
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled